Bio-Rad and Insulet outline growth strategies at healthcare forum

Bio-Rad Laboratories is implementing a multi-year strategy to enhance growth, expand profit margins, and increase free cash flow. During a Bernstein conference, Chief Financial Officer Roop Lakkaraju stated that the company is focusing on markets where it holds a competitive advantage and is utilizing a selective approach to mergers and acquisitions.

A primary growth driver for Bio-Rad is its Droplet Digital PCR business, which is used for absolute quantitation in fields such as oncology, wastewater management, and minimal residual disease detection. The company recently expanded its digital PCR capabilities through the acquisition of Stilla Technologies.

In a separate presentation at the same Bernstein forum, Insulet Corporation Executive VP and COO Eric Benjamin discussed the company’s decade-long evolution. Benjamin noted that Insulet has focused on finding innovative ways to deliver technology, such as expanding into the pharmacy channel, to improve upon traditional insulin delivery methods.